	Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis. Cancer Martinez C, Chen D, Leong R, Lum N, Xiao K, Almasri L, Kollmannsberger CK, Raman S. PMID: 42590929 [PubMed - indexed for MEDLINE]
	The Diagnostic and Prognostic Value of Immunohistochemical Markers in Bladder Cancer: A Real-World Study of 477 Patients. J Clin Med Tang X, Liu J, Zhao Q, Yang X, Yang Y, Du P. PMID: 42590225 [PubMed]
	The Use of Extracorporeal Organ Support Therapies for Acute Kidney Injury in Cancer Patients. J Clin Med Ati, Forni L, Premu. PMID: 42590126 [PubMed]
	Stem Cell-Delivered Cytosine Deaminase/5-Fluorocytosine and TRAIL Gene Therapy for Castration-Resistant Prostate Cancer: Translational Synthesis and First-in-Human Trial Concept. Int J Mol Sci Kim JH, Song M, Lee K, Lee SH, Song YS. PMID: 42589524 [PubMed - indexed for MEDLINE]
	Extracellular Alpha-Satellite DNA in Human Plasma as a Candidate Biomarker for Bladder Cancer Detection: Preliminary Evidence Using Digital PCR. Int J Mol Sci Santini N, Procino A, Ljubi, , Ugarkovi, Feliciello I. PMID: 42589489 [PubMed - indexed for MEDLINE]
	Matricellular Proteins in Bladder Cancer: Context-Dependent Roles in Tumor Promotion and Suppression. Int J Mol Sci Akhmetkaliyev A, Fritz García JHG, Sonnenberg-Riethmacher E, Riethmacher D. PMID: 42589463 [PubMed - indexed for MEDLINE]
	Integrative Bioinformatics and Machine Learning Analysis Identifies Novel Molecular Biomarkers in Prostate Adenocarcinoma. Int J Mol Sci Kurt HA, K, Çiçekliyurt MM, K. PMID: 42589294 [PubMed - indexed for MEDLINE]
	Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review. Cancers (Basel) Cano Garcia C, Moryousef J, Pinthus JH, Leong DP. PMID: 42588682 [PubMed]
	Selected Blood-Accessible Biomarkers in Prostate Cancer Radiotherapy: A PRISMA-ScR Timing-Window Framework Beyond PSA. Cancers (Basel) Gruji, Jereczek-Fossa BA, Jovanovi, , Marvaso G, Krasi, Jankovi, Peuli, Mastroleo F, Kuncman , Mutavd, Mihajlovi, Milosavljevi. PMID: 42588617 [PubMed]
	Risk of Secondary Pelvic Cancers Following Radiotherapy for Prostate Cancer. Cancers (Basel) Sayan M, Tuac Y, Hernandez C, Li YR, Coleman PW, Roach M 3rd. PMID: 42588602 [PubMed]
	Nutraceuticals in Uro-Oncology: A Structured Expert Review and Precision-Oriented Framework. Nutrients Erten F, Kalemoglu E, Kucuk O, Sahin K. PMID: 42588034 [PubMed - indexed for MEDLINE]
	Head-to-Head (18)F-rhPSMA-7.3 and (18)F-PSMA-1007 PET/CT in Recurrent Prostate Cancer: Pulmonary and Nodal Uptake as a Diagnostic Challenge. Diagnostics (Basel) Chen YS, Shen DH, Huang YT, Lee MC, Chan HP. PMID: 42587674 [PubMed]
	From Detection to Surveillance: The Evolving Role of Micro-Ultrasound in Prostate Cancer. Diagnostics (Basel) Ashrafi D, Klotz L. PMID: 42587602 [PubMed]
	BRCA Testing in Prostate Cancer: A Histopathologist's Perspective. Diagnostics (Basel) Sanguedolce F, Mazzucchelli R, Conteduca V, Maiorano BA. PMID: 42587595 [PubMed]
	PARP Inhibitor Plus Androgen-receptor Signaling Inhibitor Versus the Same Inhibitor Alone in Homologous-Recombination-Repair-Altered Metastatic Prostate Cancer Across the Hormone-Sensitive and Castration-Resistant Continuum: A Systematic Review and Meta-Analysis. Clin Genitourin Cancer Su Y, Wu R, Pan H, Yuan H. PMID: 42586923 [PubMed - as supplied by publisher]
	Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial. Eur Urol Saad F, Shore N, Vjaters E, Olmos D, Littleton N, Testa I, Mo M, Verholen F, Srinivasan S, Haresh KP. PMID: 42586872 [PubMed - as supplied by publisher]
	Enhancer Collapse Dictates PKHD1 Silencing and Centrosome-Mediated Chromosomal Instability and Metastasis in Clear Cell Renal Cell Carcinoma. Exp Cell Res Wang Y, Wang L, Deng J, Tian Z, Liang Z, Zhang H. PMID: 42586231 [PubMed - as supplied by publisher]
	Beyond the "Swan Song": Salvage Stereotactic Body Radiation Therapy for Nodal Oligorecurrence in Previously Irradiated Prostate Cancer - Lessons From the CYGNUS Retrospective Study. Int J Radiat Oncol Biol Phys Vial N, Dess RT, Zilli T. PMID: 42586129 [PubMed - in process]
	Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet Motzer RJ, McDermott R, Park SH, Burotto M, Iacovelli R, Verzoni E, Suárez C, Eto M, Cutuli HJ, Porta C, Kopp RM, Rottey S, Velasco G, Valderrama BP, Azad AA, Giorgi U, Pavic M, Tomczak P, Figlin R, Westgeest HM, Guida A, Necchi A, Schutz FA, Suelmann BBM, Haanen JBAG, Yuan SS, Perini RF, Wang D, Heng DYC, Schmidinger M, LITESPARK-011 Investigators. PMID: 42586114 [PubMed - as supplied by publisher]
	Second primary cancer risk after penile squamous cell carcinoma: A population-based study. Urol Oncol Tran HTT, Jing FZ, Van DL, Shrestha R, Lloyd GL, Otley CC, Childs DS, Nguyen GH. PMID: 42585878 [PubMed - as supplied by publisher]

Articles 1 - 20 / 180690

Page 1 of 9035



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy